RoslinCT Announces the Appointment of Dr. Derek Hei to its Scientific Advisory Board
17.8.2023 15:00:00 EEST | Business Wire | Press release
RoslinCT, a leading contract development and manufacturing organization (CDMO) for Advanced Cell and Gene therapies, announced the appointment of Derek Hei, Ph.D., to its Scientific Advisory Board (SAB). The SAB is comprised of cell and gene therapy pioneers with extensive experience, providing valuable insight into a range of topics for the development and manufacturing of advanced therapies.
Dr. Hei is Chief Technology Officer (CTO) at Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines. Dr. Hei’s deep expertise in the cell therapy space spans over two decades and has been leading manufacturing teams at biotechnology companies. He previously served as Chief of Manufacturing and Tech Ops at BlueRock Therapeutics, and SVP of Preclinical and Clinical Manufacturing, Cell and Gene Therapies, at Vertex Pharmaceuticals, where he was responsible for leading chemistry, manufacturing, and controls activities for multiple cell and gene therapy programs.
“Dr. Hei brings significant knowledge across many areas of cell and gene therapy development, including the production of cGMP-compliant cell therapies for clinical trials, and gene-edited induced pluripotent stem cell lines.” said Patrick Lucy, President and CEO of RoslinCT US, “He brings a unique and complementary perspective to our Scientific Advisory Board, and we are honored to welcome him.”
Peter Coleman, CEO of RoslinCT UK, commented: “The broad scientific expertise of our advisory board plays a crucial role in the development of advanced therapies by providing expert guidance, ensuring scientific rigor, and promoting safety and efficacy to accelerate innovation and improve patient outcomes. This is key to ensuring our continued growth. I am delighted to welcome Dr. Hei to our group.”
Dr. Hei joins the five board members previously appointed: Kenneth LeClair, Ph.D., Chair of the Board, Michael Chambers, Co-founder of Aldevron, Margit Jeschke, Ph.D., Independent Consultant, Michael Kalos, Ph.D., Founder and Managing Director at Next Pillar Consulting, and Michael Mendicino, Ph.D., Founder, President and Chief Consultant at Hybrid Concepts International.
About RoslinCT
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and supporting the development and future commercialization of cell therapies based on a broad range of cell types with an advanced program utilizing CRISPR-edited stem cell-based therapy.
Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation.
With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide.
Discover more about our services at www.roslinct.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230817175472/en/
Contact information
Media Contact Information:
Carrie Zhang
Senior Director of Marketing
RoslinCT
E-mail: carrie.zhang@roslinct.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 20:10:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic cancer and colorectal cancer, our TGFβR2×PD-1 bispecific antibody in microsatellite stable colorectal cancer and our CDK2 inhibitor in recurrent epithelial ovarian cancer – investigational approaches that reflect our focus on areas where there is significant need for novel therapies." Details on key data presentations at ESMO include: Rapid Oral Presentations INCB161734 (KRAS G12D) Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Mono
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 15:24:00 EEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 13:30:00 EEST | Press release
The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025, approaching the size of the entire US e-commerce market, according to market data cited in the report. Yet 68% of consumers in North America and 67% in Europe have never once bought a product through social media, and roughly two-thirds
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 13:30:00 EEST | Press release
Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, development and commercialization. The collaboration now runs across continents, between Aqemia researchers in Paris and London and San
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS, Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 13:17:00 EEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom